Toutes les photos(1)

Documents

L0750500

Lorazepam

Name: Lorazepam
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(±)-Lorazepam, 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₁₅H₁₀Cl₂N₂O₂

Numéro CAS:

846-49-1

Poids moléculaire :

321.16

Numéro MDL:

MFCD00063406

Code UNSPSC :

41116107

ID de substance PubChem :

329817375

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 4

1 of 4

USP

1370338

Lorazepam Related Compound B

USP

1370349

Lorazepam Related Compound C

Supelco

S-098

(-)-Scopolamine hydrobromide solution

HL60 Cell Line human

Qualité

pharmaceutical primary standard

Famille d'API

lorazepam

Fabricant/nom de marque

EDQM

Contrôle du médicament

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES

OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

Clé InChI

DIWRORZWFLOCLC-UHFFFAOYSA-N

Informations sur le gène

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Étalons des instituts de métrologie et des pharmacopées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lorazepam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1370327

Y0000576

Lorazepam for system suitability, European Pharmacopoeia (EP) Reference Standard

1370305

Lorazepam, United States Pharmacopeia (USP) Reference Standard

1370338

Y0000718

Lorazepam impurity D, European Pharmacopoeia (EP) Reference Standard

1370349

1370350

1370360

Mention d'avertissement

Warning

Mentions de danger

H361d

Conseils de prudence

P201 - P202 - P280 - P308 + P313 - P405 - P501

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Orofacial dyskinesia induced by nasal Ritalin(R) (methylphenidate) sniffing: a rare case report from Switzerland.

G Marti et al.

Human & experimental toxicology, 32(3), 332-334 (2012-11-24)

Ritalin® (methylphenidate) is an amphetamine-like prescription stimulant commonly used in the treatment of attention deficit hyperactivity disorder in children and adults. Recently, the recreational use of Ritalin has increased, particularly among young adults. Well-known symptoms of intoxication include signs of

Delirious mania: detection, diagnosis, and clinical management in the acute setting.

Natalie L Jacobowski et al.

Journal of psychiatric practice, 19(1), 15-28 (2013-01-22)

Delirious mania is a severe but under-recognized neuropsychiatric syndrome characterized by the rapid onset of delirium, mania, and psychosis, not associated with a prior toxicity, physical illness, or mental disorder. Catatonia is often a prominent feature of the syndrome. While

A 59-year-old woman who is awake yet unresponsive and stuporous after liver transplantation.

Insung Chung et al.

Chest, 143(4), 1163-1165 (2013-04-03)

Persistent catatonia for 1.5 years finally resolved with electroconvulsive therapy.

Feridun Bülbül et al.

The journal of ECT, 29(1), e1-e1 (2013-02-21)

Despite having been previously associated with schizophrenia, catatonia is more often associated with mood disorders and factors related to general medical conditions. Benzodiazepines are recommended as the first option in treatment of catatonia. For patients who do not sufficiently respond

Successful treatment of co-occurring catatonia and obsessive-compulsive disorder with concurrent electroconvulsive therapy and benzodiazepine administration.

Michael Makhinson et al.

The journal of ECT, 28(3), e35-e36 (2012-08-24)

Catatonia, associated with a variety of medical and psychiatric conditions such as mood disorders and schizophrenia, is frequently treated with either benzodiazepines or with electroconvulsive therapy (ECT) in treatment-resistant cases. Simultaneous treatment with both is usually avoided. Here, we report

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique